Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Ranibizumab for Refractory Wet AMD
NCT03071055Phase 2Completed
- Sponsor
- Centricity Research
- Start
- Oct 2017
- Primary completion
- Jun 2019
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in exudative age-related macular degeneration, sponsored by Centricity Research. Started Oct 2017; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT03071055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071055.